Episode 218: Statin Therapy Fundamentals
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Episode 218: Statin Therapy Fundamentals” inside PodZeus.
In Episode 218 of Rio Bravo Q Week, Dr. Hector Arias welcomes fourth-year medical student Zohal to discuss the fundamentals of statin therapy in primary and secondary cardiovascular prevention. The episode provides a comprehensive overview of statins, their mechanism of action by inhibiting HMG-CoA reductase to lower LDL cholesterol, and their critical role in reducing atherosclerotic cardiovascular disease (ASCVD) risk. The hosts explore the historical development of statins, from early cholesterol research in the 1900s to the approval of lovastatin in 1987, and highlight the transformative impact of clinical trials in the 1990s and 2000s. A major focus is on updated 2026 guidelines from the American College of Cardiology and American Heart Association, which introduce the PREVENT risk calculator for assessing 10- and 30-year ASCVD risk starting at age 30, with new recommendations for statin use in borderline (3–5%) and intermediate (5–10%) risk individuals, as well as expanded indications for patients with diabetes, chronic kidney disease, HIV, and those over 75. The episode emphasizes shared decision-making, lifestyle modification as first-line prevention, and the importance of staying current with evolving guidelines. The conversation concludes with a reflection on the quiet, long-term impact of preventive medicine in primary care, where success is measured in events that never happen.
Use the PREVENT calculator to assess 10- and 30-year ASCVD risk starting at age 30, with risk categories: low (<3%), borderline (3–5%), intermediate (5–10%), and high (>10%).
Statins are recommended for primary prevention in adults aged 40–75 with one or more risk factors (e.g., diabetes, hypertension, smoking) and a 10-year ASCVD risk ≥10%, or in those with diabetes, CKD stages 3–4, or HIV regardless of LDL.
High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL by ≥50%, while moderate-intensity statins (atorvastatin 10–20 mg, rosuvastatin 5–10 mg) reduce LDL by 30–49%.
Lifestyle modification—including diet, exercise, and smoking cessation—remains the cornerstone of cardiovascular prevention, but statins provide the greatest benefit in higher-risk patients.
Shared decision-making is essential when prescribing statins for primary prevention due to potential side effects like myalgia, liver enzyme elevation, rhabdomyolysis, and a small increased risk of type 2 diabetes.
…and 3 more takeaways available in PodZeus
Introduction to Statin Therapy and Primary Prevention
Dr. Hector Arias introduces the episode and guest Zohal, a fourth-year medical student, emphasizing the importance of primary prevention in family medicine and setting the stage for a deep dive into statin therapy fundamentals.
What Are Statins and How Do They Work?
Zohal explains the mechanism of statins—blocking HMG-CoA reductase to reduce LDL cholesterol—and clarifies the roles of LDL (bad cholesterol) and HDL (good cholesterol) in cardiovascular risk.
Historical Development and Clinical Impact of Statins
The episode traces the history of statin research from early 20th-century animal studies to the 1987 approval of lovastatin, highlighting pivotal clinical trials that proved statins reduce heart attacks, strokes, and mortality.
Guidelines and Risk Assessment: USPSTF and the 2026 ACC/AHA Update
“You can start using this calculator at age 30. So it is considered low risk if it's less than 3%. Borderline between three and five. Intermediate between five and 10. And high risk, more than 10%.”
Statin Intensity, Side Effects, and Shared Decision-Making
“Shared decision making is essential when prescribing statins for primary prevention.”
“Your highest victories are often the events that never happen.”
“Shared decision making is essential when prescribing statins for primary prevention.”
“You can start using this calculator at age 30.”
Host
Guest
Zohal
person
Hector Arias
person
LDL Cholesterol
other
American Heart Association
organization
Atorvastatin
product
Rosuvastatin
product
American College of Cardiology
organization
HDL Cholesterol
other
U.S. Preventive Services Task Force
organization
PREVENT
product
Episode 219: Chronic Pain and Functionality in Cancer Survivors
Rio Bravo qWeek • 15m • 4/13/2026
Episode 220: Approach of Insomnia in Adults
Rio Bravo qWeek • 28m • 4/20/2026
Episode 221: Insomnia Pharmacotherapy in Adults
Rio Bravo qWeek • 19m • 4/24/2026
Episode 222: Antibiotic Resistance
Rio Bravo qWeek • 17m • 5/1/2026
Episode 223: Oncogenic Viruses
Rio Bravo qWeek • 19m • 5/8/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Episode 218: Statin Therapy Fundamentals” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime